Patient P-03110
Therapy response
Declining
Tolerance
Deteriorating
GI state
Deteriorating
Inflammatory state
Deteriorating
Nutritional resilience
Declining
Discontinuation risk
67%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 ONX-7 started — Baseline state S15
- Day 58 Trajectory diverged from prediction — Observed response fell below the model's expected path.
- Day 63 GI-04 recommended — GI Support Protocol GI-04
- Day 64 Patient accepted — Started GI-04 in the companion
- Day 65 SC-12 recommended — Supportive Compound SC-12
- Day 66 Patient accepted — Started SC-12 in the companion
- Day 72 GI symptom burden −37% vs expected — GI Support Protocol GI-04
- Day 72 GI symptom burden −22% vs expected — Supportive Compound SC-12
- Day 78 Tolerance state changed — Unstable → Improving
- Day 78 Tolerance state changed — Unstable → Improving
What changed?
Trajectory began diverging from predicted response on Day 58.
Primary contributors, last 14 days
- GI instability+14
- Nutritional resilience-7
- Inflammatory activity+5
- Toxicity+4
- Treatment adherence-3
What helped?
- GI Support Protocol GI-04Day 63Result: symptom burden −37%
- Supportive Compound SC-12Day 65Result: symptom burden −22%
LIFE OS recommendation
Dosing / Timing Recommendation DT-01
64%
probability of meaningful tolerance improvement
- 284 similar trajectories
- 82% showed improvement
- median effect visible after 5 days
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Mucosal barrier integrity ↓90
- DNAFUT2 non-secretor lowers mucosal fucosylation
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 50 and rising
- WearableSleep 5.8 h, below personal baseline
- Butyrate / short-chain fatty acid production ↓80
- MicrobiomeButyrate capacity 36/100
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
- Autonomic recovery ↓65
- WearableResting HR 77 bpm
- Wearable1,131 steps/day
- WearableShort sleep window
- Inflammatory signalling ↑50
- DNAIL6 -174 variant raises baseline inflammatory tone
- BloodInflammatory load index 43
DNA
Fictional pharmacogenomic panel
- FUT2 rs601338 AA (non-secretor)Reduced mucosal fucosylation
- IL6 -174 G/CHigher inflammatory tone
- CYP2D6 Intermediate metabolizerExpected exposure
- MTHFR C677TReduced folate turnover
Microbiome
Shannon diversity 3 · butyrate capacity 36/100
- Akkermansia muciniphilaLow
- Faecalibacterium prausnitziiLow
- Bacteroides fragilisNormal
- Bifidobacterium longumLow
- EnterobacteriaceaeNormal
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 52 ms
- Sleep
- 6.2 h
- Steps
- 2,166
- Resting HR
- 75 bpm
Daily log: GI score 50, nutritional resilience 47, adherence 56.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
- Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
- Track each bowel movement today: time, stool form, urgency, overnight waking
- A 15-minute walk after lunch
- Protect a 7.5-hour sleep window; screens off 30 minutes before
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the scheduled dose as agreed with your care team
- Electrolyte solution, one sachet after any loose stool
- Fictional demo item: oral nutrition supplement with lunch
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-03070 | 46% | S14 | GI-04 | improved | 51 |
| P-03300 | 46% | S14 | GI-04 | improved | 46 |
| P-03090 | 45% | S02 | GI-04 | improved | 48 |
| P-03123 | 41% | S14 | GI-04 | improved | 50 |
| P-03145 | 41% | S14 | GI-04 | improved | 51 |
| P-03146 | 41% | S14 | GI-04 | improved | 53 |
| P-03279 | 37% | S14 | GI-04 | improved | 57 |
| P-03289 | 37% | S03 | SC-12 | improved | 54 |
| P-03046 | 35% | S20 | GI-04 | no change | 53 |
| P-03159 | 35% | S14 | GI-04 | improved | 37 |
| P-03225 | 35% | S19 | GI-04 | improved | 50 |
| P-03405 | 35% | S16 | — | — | 62 |